Abstract
THU591 - Antiviral and antitumor activity of SCG101, an autologous HBV-specific T cell receptor engineered T cell (TCR-T) therapy in HBV-related advanced hepatocellular carcinoma (HCC) patients after receiving ≥2 prior lines of systemic therapies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have